SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Norris Medicines - Quaterly Results

25 May 2023 Evaluate
The sales figure stood at Rs. 12.13 millions for the March 2023 quarter. The mentioned figure indicates a growth of about 44.58% as compared to Rs. 8.39 millions during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -5.43 millions as compared to Net Loss of Rs. -22.33 millions of corresponding quarter ended March 2022 Operating profit Margin for the quarter ended March 2023 improved to 5.58% as compared to -4.15% of corresponding quarter ended March 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 12.13 8.39 44.58 83.58 94.38 -11.44 83.58 94.38 -11.44
Other Income 0.12 -0.04 -400.00 0.14 0.26 -46.15 0.14 0.26 -46.15
PBIDT 5.58 -4.15 -234.46 9.38 -0.46 -2139.13 9.38 -0.46 -2139.13
Interest 3.69 0.82 350.00 15.00 14.82 1.21 15.00 14.82 1.21
PBDT 1.89 -4.97 -138.03 -5.62 -15.28 -63.22 -5.62 -15.28 -63.22
Depreciation 1.76 6.57 -73.21 6.30 6.57 -4.11 6.30 6.57 -4.11
PBT 0.13 -11.54 -101.13 -11.92 -21.85 -45.45 -11.92 -21.85 -45.45
TAX 5.56 10.79 -48.47 5.56 10.79 -48.47 5.56 10.79 -48.47
Deferred Tax 5.56 10.79 -48.47 5.56 10.79 -48.47 5.56 10.79 -48.47
PAT -5.43 -22.33 -75.68 -17.48 -32.64 -46.45 -17.48 -32.64 -46.45
Equity 99.26 99.26 0.00 99.26 99.26 0.00 99.26 99.26 0.00
PBIDTM(%) 46.00 -49.46 -193.00 11.22 -0.49 -2402.59 11.22 -0.49 -2402.59

Norris Medicines Share Price

14.97 0.22 (1.49%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×